Vasculitis covers a group of diseases where blood vessels become inflamed, ranging from giant cell arteritis to ANCA-associated vasculitis. Treatment has shifted away from heavy steroid use toward targeted biologics like rituximab and avacopan, which dramatically reduce steroid exposure and side effects.
What's actually going on in research
Trials are testing newer biologics, complement inhibitors like avacopan, IL-6 blockers for giant cell arteritis, and treatments aimed at inducing and maintaining remission with less steroid. Researchers are also studying rare forms like Takayasu arteritis and Behcet disease, and biomarkers for relapse.
Steroid-sparing drugs
Avacopan and other targeted drugs are letting patients with ANCA-associated vasculitis taper off steroids faster, cutting infections, weight gain, and bone loss.
Biologics for giant cell arteritis
Tocilizumab is changing treatment for the most common large-vessel vasculitis. New IL-6 and other biologics are being tested for harder-to-treat cases.
Maintaining remission
Trials are testing how long to continue rituximab and other biologics to keep vasculitis in remission while limiting infection risk and other side effects.
What to know before you search
Eligibility often depends on vasculitis type (ANCA-associated, giant cell, Takayasu, etc.), organ involvement, ANCA antibody status, and prior treatments.
What types of trials are currently open
- Treatment trials — Testing biologics and targeted drugs to bring vasculitis into remission with less steroid use.
- Maintenance trials — Testing treatments given during remission to prevent vasculitis from coming back.
- Therapy strategy trials — Testing approaches that taper steroids faster or replace them entirely.
- Observational studies — Following people with vasculitis to understand relapse patterns and long-term outcomes.
- Rare vasculitis trials — Testing treatments for less common forms like Takayasu, Behcet, and IgA vasculitis.
Recently added Vasculitis trials
Global Initiative on Takayasu Arteritis (GITA)
Takayasu's Arteritis Global Registry aims to bring a large group of patients from different parts of the world to analyse and compare the patients' demographic, clinical, laboratory, radiological and prognostic features with outcomes, approaches to diagnosis, assessment, management and therapeutic interventions in different centers. The present project provides for both a retrospective and a prospective longitudinal study. The study is designed as retrospective for patients already diagnosed with TAK and treated with available treatments. Also, the study is designed as prospective for patients diagnosed with TAK after the initiation of the Registry or the adhesion to the project. This is thought as a multicentre, international study addressed to all Centers that will want to contribute to the present project. The study is non-interventional: demographic, clinical and therapeutic data required over time are collected with the routine diagnostic, clinical and therapeutic procedures usually carried out for the optimal management of patients and according with good clinical practice.
Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.
Find Vasculitis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.